Karpus Management, Inc. filed a Schedule 13G with the SEC on November 13, 2026, disclosing beneficial ownership of 3,300,023 shares of common stock in Drugs Made In America Acquisition II Corp., representing 5.18% of the class as of September 30, 2026.

Key Highlights

  • Beneficial Ownership: Karpus Management, Inc. reported aggregate beneficial ownership of 3,300,023 shares of common stock in Drugs Made In America Acquisition II Corp.
  • Percent of Class: The 3,300,023 shares represent 5.18% of the class of securities, according to the filing.
  • Sole Voting and Dispositive Power: Karpus holds sole voting power and sole dispositive power over all 3,300,023 shares, with no shared voting or dispositive power reported.
  • Triggering Event Date: The date of the event requiring the filing was September 30, 2026.
  • Shares Held in Client Accounts: According to the filing, the shares are owned directly by accounts managed by Karpus.
  • Parent Company: The filing states that Karpus is controlled by City of London Investment Group plc, which is listed on the London Stock Exchange, but notes that effective informational barriers have been established such that voting and investment power is exercised by Karpus independently of City of London Investment Group plc.

Karpus Management's Schedule 13G Filing for Drugs Made In America Acquisition II Corp.

Karpus Management, Inc., doing business as Karpus Investment Management, filed a Schedule 13G disclosing a 5.18% beneficial ownership position in the common stock of Drugs Made In America Acquisition II Corp. (CUSIP: G2851K104). The filing identifies Karpus as a registered investment adviser under Section 203 of the Investment Advisers Act of 1940, organized as a New York corporation with its principal office at 183 Sully's Trail, Pittsford, New York 14534.

According to the filing, Karpus holds 3,300,023 shares with sole voting power and sole dispositive power, and reports zero shares subject to shared voting or shared dispositive power. The shares are held in accounts managed by Karpus on behalf of its clients. The filing notes that Karpus is controlled by City of London Investment Group plc, but states that "effective informational barriers have been established between Karpus and CLIG such that voting and investment power over the subject securities is exercised by Karpus independently of CLIG," and that attribution of beneficial ownership between the two entities is therefore not required, citing SEC Release No. 34-39538 (January 12, 1998).

The issuer, Drugs Made In America Acquisition II Corp., is listed with its principal executive offices at 420 Lexington Avenue, Suite 1402, New York, NY 10170. The filing was signed by Jodi L. Hedberg, Chief Compliance Officer of Karpus Management, Inc., and certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

What Was Disclosed

Karpus Management, Inc. disclosed via Schedule 13G that it beneficially owns 3,300,023 shares, or 5.18%, of the common stock of Drugs Made In America Acquisition II Corp. as of September 30, 2026, with all voting and dispositive power held solely by Karpus.